Trials
Newly Diagnosed / Upfront Setting:
A randomized phase 2 study of CHO(E)P vs CC-486- CHO(E)P vs duvelisib CHO(E)P in previously untreated CD30 negative peripheral T-cell lymphomas.
A dual-cohort, open-label, phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression
Relapsed/Refractory Setting:
A Phase 1/2, Open-Label, First-in-Human, Multiple Ascending Dose Multicenter Study of MT-101 in Subjects with CD5+ Relapsed/ Refractory Peripheral T Cell Lymphoma
A phase I/II study of ABC008 in T-cell large granular lymphocytic leukemia (T-LGLL)
A Phase 1, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Adult Subjects With Relapsed or Refractory T or B Cell Malignancies.
Clinics
Multidisciplinary Cutaneous Lymphoma Clinic
The cutaneous lymphoma clinic is a multidisciplinary clinic comprised of dermatologist (Dr Steven Chen), radiation oncologist (Dr Chirayu Patel) and lymphoma physicians (Drs Jeffrey Barnes and Jain). This is a specialty one stop clinic in which we offer comprehensive and integrated care for patients with cutaneous lymphomas ranging from diagnosis to treatments. This clinic is located within the lymphoma clinic in the Yawkey Building at 32 Fruit Street, Massachusetts General Hospital.
Contact: To schedule an appointment, please call: 617.724.4000.